Incyte (INCY): Novartis Data Bodes Well For Incyte - RBC

October 25, 2016 7:51 AM EDT
Get Alerts INCY Hot Sheet
Price: $117.22 --0%

Rating Summary:
    21 Buy, 2 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 19 | Down: 13 | New: 9
Trade INCY Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

RBC Capital analyst, Simos Simeonidis, reiterated his Outperform rating on shares of Incyte (NASDAQ: INCY) after Novartis (NYSE: NVS), INCY's ex-US parter, reported $149M in 3Q16 Jakavi sales, beating consensus of $147M but lower than his $153M estimate. That said, royalties could be up 57% y/y.

Full detail will come out on INCY's 3Q16 earnings call, Tuesday November 1st, mid morning.

No change to the price target of $113.

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $88.18 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

RBC Capital, Earnings

Add Your Comment